By J. Boss. LaGrange College.
The ratings (yes/no/other) on the different items are then used by reviewers to assess overall risk of bias as good (low risk of bias) buy 250 mg chloramphenicol otc virus x the movie, fair (susceptible to some bias) or poor (significant risk of bias) generic 500mg chloramphenicol amex bacteria 9gag. For case-series and case-reports generic chloramphenicol 500 mg on line infection nail bed, we used the critical appraisal checklists from the Joanna Briggs Institute  250 mg chloramphenicol free shipping yeast infection. These checklists are a series of 8 to 10 closed questions (yes/ no/unclear/not applicable) which help form an overall appraisal for each study assessed. For standardisation, we used this assess- ment to classify studies as low risk, high risk or unclear risk of bias. If a decision could not be reached on bias assessments, an additional inves- tigator made a decision. This approach specifies four levels of quality; high, moderate, low and very low. Data synthesis and analysis To summarise the effects of low-carbohydrate diets on type 1 diabetes outcomes in controlled trials, we extracted mean outcome values for the intervention and control groups at baseline and follow-up. For other studies with only an intervention group or for trials where only one participant group was relevant to our study, we extracted mean outcome values for the inter- vention or observed group at baseline and follow-up. Standard deviations and/or standard errors, sample sizes, follow-up time and published levels of significance (i. If no P-value was published and raw outcome data were available, the P-value was calculated using the R Statistical Language (R version 3. A meta-analysis was not able to be conducted due to obvious heterogeneity and we used text and tabular format to summarise the outcome data of all low-carbohydrate diets. Where no specific pre- scription was available and compliance to the intervention was reported, studies were classified according to the reported dietary intake data of participants. Results Literature search results The database search identified 2724 possibly relevant studies that were screened by titles and abstracts (Fig 1). A further 2645 records were excluded with 79 full-text articles subsequently assessed for eligibility. Eleven additional records were identified through searching the reference lists of included studies. The duration of exposure to a low-carbohydrate diet ranged from two weeks to five years. The two controlled trials com- pared a low-carbohydrate diet (intervention) to a higher-carbohydrate diet (comparator) using either a crossover  or parallel  design. All other studies compared a low-carbohy- drate diet (intervention) to baseline or usual diet (comparator). Study Details Populationa Interventionb Comparatorb Insulin Protocolc Outcomed Anderson 1991 . Information was provided on the amount of insulin likely needed to match 5075 g of carbohydrate per day. Group education course (whole day pen device that enables delivery of followed by 4 x 3 h sessions over 4 wk). Phone calls and injections, and no more than 9 h office visits used to tailor individual between evening basal dosages and regimen of each patient. Diabetes duration (xD) is given as the mean (to nearest whole year) and range of n participants. Not controlledResearchers did not make an acceptable attempt to control for the effect of insulin and/or only observed insulin protocols (i. All outcomes Results for all primary and secondary outcomes are presented in Table 2. Effect sizes were not calculated because raw outcome data were not available for all studies and most outcomes were inconsistently reported. Results for our primary out- come (HbA1c) were available from eight of nine studies reviewed. HbA1c Eight studies investigated the effect of a low-carbohydrate diet on glycaemic control using HbA1c [8, 10, 2024, 26] (Table 2). One study  reported a follow-up value for HbA1c but did not provide baseline data so was not included for this outcome. Of the two studies that com- pared a low-carbohydrate diet to a higher-carbohydrate diet [10, 20], neither showed a signifi- cant difference between groups at follow-up. Effect of intervention and comparator diets on type 1 diabetes management outcomes (primary and secondary). This was converted to 730 via simple calculation (2 x 365) and may not be an accurate representation of a full year. Levels of significance could not be calculated or obtained in three studies due to inadequate sample size  and lack of raw participant data [8, 24]. Risk of bias in one  was rated low in four domains and unclear in four domains. The other controlled trial  was rated low in seven domains and unclear in one domain. Of the pre-post intervention studies (S9S13 Tables), two were rated as fair quality [8, 21] and two were rated as poor. The poor-quality studies did not attempt to control for the confounding influence of insulin therapy on HbA1c. One case-series  had an overall risk of bias of high and the other case-series  had a low risk of bias (S14 Table). Both reports had clear criteria for inclusion, valid methods for identification of type 1 diabetes, clear outcome results of cases and appropriate statistical analyses. The case-report  had an over- all appraisal of low risk of bias (S15 Table). The five cate- gories used for downgrading the quality of evidence were assessed and included in Table 3. Categories were assigned a rating of zero if the appropriate statistical analyses required to con- fidently downgrade the evidence based on the criteria were not able to be performed, or if it could be appropriately justified that the evidence should not be downgraded for that category. Discussion The present systematic review is the first of its kind to present all available evidence on low- carbohydrate diets for the management of type 1 diabetes. Consistency Consistency could not be statistically assessed as no meta-analysis was performed (0). Precision Precision could not be statistically assessed as no meta-analysis was performed (0). Publication It is unlikely that additional studies have been conducted on this specific topic due to bias the perceived risk involved in reducing carbohydrate below recommended levels in patients with type 1 diabetes. We were unable to create a funnel plot to support this judgement as this requires at least 10 studies and there are only 8 studies for this outcome (0). We were also unable to determine whether primary nutrition studies of low-car- bohydrate diets have different levels of effect depending on the degree of carbohydrate restric- tion. However, for all studies reporting a significant change in HbA1c, the direction of change was similar with low-carbohydrate interventions or observed intakes. This review highlights a limited body of evidence and suggests the need for more high-quality prospective trials exam- ining the effect of low-carbohydrate diets in the management of type 1 diabetes. Clinical significance of results The United Kingdom Prospective Diabetes Study highlighted the importance of lowering HbA1c to reduce the risk of micro and macrovascular complications in patients with diabetes . Further, Juutilainen and colleagues (2008) reported that in type 1 diabetes patients, a 1% rise in HbA1c increased individual risk of cardiovascular mortality by 52. Cardiovascu- lar diseases are the main cause of morbidity and mortality in diabetes, affecting about 55% of patients, compared to 24% of people without diabetes . Our review identified statistically significant improvements in glycaemic control in 3 of 8 studies (n > 1) that reported a change in mean HbA1c with a low-carbohydrate diet [8, 21, 24]. The excessive use of insulin that is often required to achieve glycaemic control in type 1 diabetes increases susceptibility to severe hypoglycaemia and may lead to some measure of hyperinsulinemia .
Association between smoking and chronic N=8 cheap chloramphenicol 500mg with amex antibiotics root canal,832 N=8 order chloramphenicol 500mg fast delivery termin 8 antimicrobial preservative,452 kidney disease: A case control study cheap chloramphenicol 500mg with visa antibiotic keflex breastfeeding. Saxagliptin and cardiovascular out- comes in patients with type 2 diabetes mellitus buy 250 mg chloramphenicol otc bacteria bacillus. Effect of sitagliptin on cardiovascu- for eligibility N=266 lar outcomes in type 2 diabetes. Effects of liraglutide on clini- cal stability among patients with advanced heart failure and reduced ejection control or study design fraction: A randomized clinical trial. Preferred Reporting Items for Systematic Reviews and Meta- events in type 2 diabetes. Study to evaluate the effect of dapagliozin on the incidence of worsening heart doi:10. Can J Diabetes 42 (2018) S201S209 Contents lists available at ScienceDirect Canadian Journal of Diabetes journal homepage: www. Diabetes is the leading cause of kidney disease All individuals with chronic kidney disease should be considered at high in Canada (4). Kidney disease can be a devastating complication, risk for cardiovascular events and should be treated to reduce these risks. The development and progression of renal damage in diabetes can be as it is associated with signicant reductions in both length and reduced and slowed through intensive glycemic control and optimization quality of life (5,6). Progression of chronic kidney disease in diabetes can in diabetes can be seen, including diabetic nephropathy, ischemic also be slowed through the use of medications that disrupt the renin angio- nephropathy related to vascular disease, hypertensive nephro- tensin aldosterone system. Clinical studies have suggested that one- Diabetic Nephropathy quarter to one-half of people with diabetes and signicant kidney function impairment do not have albuminuria (1820). These studies The classical description of diabetic nephropathy is a slow and suggest that testing for albuminuria may be insucient in identi- progressive increase in albuminuria, followed later in the disease fying all people with diabetes who have renal disease. Key risk factors include long dura- with kidney disease other than diabetic nephropathy. Many of these matter whether the renal diagnosis is one of diabetic nephropa- risk factors are modiable. Identication of hyperltration is not clinically useful, as lated to diabetes and require additional testing or referral, and it is dicult to determine from routine testing and is not present possible renal biopsy (2225). Persistent albumin- uria is considered the earliest clinical sign of diabetic nephropa- thy. Initially, small amounts of albumin are leaked, below the Screening for Chronic Kidney Disease in People with Diabetes detection threshold of a urine dipstick. However, late in the overt kidney disease phase, the rate of ately at the time of diagnosis in this group. Thus, signicant renal dysfunction is not usually seen until late in the course of diabetic nephropathy (16). Screening for Albuminuria It is important to note that the rate of progression can vary between individuals, and that the clinical markers of the disease When screening for albuminuria, the test of choice is the random (i. In addition, tran- sient and benign increases in albuminuria can be provoked by a number of factors (3337) (Table 3). When such conditions are present, screening for kidney disease should be delayed to avoid positive results that are not caused by renal damage. Furthermore, diagnosing a person as having albuminuria requires the elevated urinary albumin level to be persistent. A 24-hour urine for higher levels of renal function (42), most medical laboratories across creatinine clearance can be used in individuals where there are con- Canada now use this formula. This can be delayed ve years from the onset of type 1 diabetes, but should begin immediately at the time of diag- nosis of type 2 diabetes. In addition, serum electrolytes should be ordered along with any other testing that is indicated. The presence of clinical or laboratory abnormalities suggesting non- diabetic kidney disease indicates the need for appropriate work-up or referral (see Recommendation 9 for more details). Optimal glycemic control established as soon after diagnosis as When such conditions are present, assessment of the level of kidney possible will reduce the risk of development of diabetic kidney function may be clinically necessary, but should not be used to assess disease (4448). Because renal function can be transiently depressed, be slowed through intensive glycemic control (44,49). However, diabetic nephropathy, its presence should lead to the consider- none of these studies demonstrated a reduction in cardiovascular ation of other urologic or nephrologic conditions. This indicates that the optimal A1C may differ for priate assessment for the cause of their disease. For most adults Although 24-hour collections are not needed for routine screen- with diabetes, a target A1C of <7. It should be noted that these als should be counseled to discard the rst morning urine on the studies examined people with early renal disease and diabetes. Evi- day of collection, and then collect all subsequent urine for a 24-hour dence supporting intensive glycemic control is lacking in people with period, including the rst morning urine of the next day. Consideration should be given to providing people with a sick-day medication list, instruct- 1. Screening should commence at diagnosis of diabetes in indi- viduals with type 2 diabetes and 5 years after diagnosis in adults with type 1 diabetes and repeated yearly thereafter [Grade D, Consensus]. People with diabetes should be referred to a specialist with expertise in urinary potassium excretion. Unable to remain on renal-protective therapies due to adverse effects, advice should be sought from a renal specialist. S88 microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. Markers of and risk factors for the develop- ment and progression of diabetic kidney disease. The course of kidney function in type 2 Relevant Appendices (non-insulin-dependent) diabetic patients with diabetic nephropathy. Therapeutic Considerations for Renal Impairment normotensive type 1 diabetic patients. Clinical versus histological diagno- Related Websites sis of diabetic nephropathyis renal biopsy required in type 2 diabetic patients with renal disease? Development and progression of renal insuf- resources/kidneywisetoolkit/) ciency with and without albuminuria in adults with type 1 diabetes in the Ontario Renal Network: KidneyWise Clinical Toolkit (available at diabetes control and complications trial and the epidemiology of diabetes inter- ventions and complications study. The nephropathy of non-insulin- dependent diabetes: Predictors of outcome relative to diverse patterns of renal injury. Retinopathy as a predictor of reports grants from Boehringer Ingelheim-Lilly, Merck, Janssen, Sano other diabetic complications. The validity of random urine specimen albumin sonal fees from Janssen and Merck, outside the submitted work. Yonsei Med J Senior reports personal fees from Abbott, Boehringer Ingelheim, Eli 1999;40:405. Invalidity of simple concentration-based screening tests for early nephropathy due to urinary grants and personal fees from Novo Nordisk, Sano, and AstraZeneca; volumes of diabetic patients. The urine protein to creatinine ratio as a is the Medical Director of the Clinical Islet Transplant Program at predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. Receiver operating characteristic curve References analysis favors albumin-to-creatinine ratio over albumin concentration. Effect of duration of type I diabetes on the dren and adolescents with type 1 (insulin dependent) diabetes. Diabetologia prevalence of stages of diabetic nephropathy dened by urinary albumin/ 1981;21:4957. Albuminuria predicting outcome in diabetes: Incidence of micro-albuminuria in type 1 (insulin-dependent) diabetes mellitus.
9 of 10 - Review by J. Boss
Votes: 65 votes
Total customer reviews: 65